Cargando…

A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity

Treatment response to clopidogrel is associated with CYP2C19 activity through the formation of the active H4 metabolite. The aims of this study were to develop a physiologically based pharmacokinetic (PBPK) model of clopidogrel and its metabolites for populations of European ancestry, to predict the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duong, Janna K., Nand, Romina A., Patel, Aarti, Della Pasqua, Oscar, Gross, Annette S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934724/ https://www.ncbi.nlm.nih.gov/pubmed/35307978 http://dx.doi.org/10.1002/prp2.946

Ejemplares similares

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016)

The Role of Global and Local Ancestry on Clopidogrel Response in African Americans
por: Yang, Guang, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Genotypic and Allelic Variability in CYP19A1 among Populations of African and European Ancestry
por: Starlard-Davenport, Athena, et al.
Publicado: (2015)

Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?
por: Shebley, Mohamad
Publicado: (2018)

Discovery of Ancestry-specific Variants Associated with Clopidogrel Response among Caribbean Hispanics
por: Yang, Guang, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug–Drug Interaction Between Clopidogrel and Dasabuvir
por: Shebley, M, et al.
Publicado: (2017)

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
por: Varenhorst, Christoph, et al.
Publicado: (2009)

Bacterial growth dynamics and pharmacokinetic–pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice
por: Muliaditan, Morris, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives
por: Zhang, Yan-Jiao, et al.
Publicado: (2017)

European NSTEMI guidelines—return of clopidogrel?
por: Dannenberg, Lisa, et al.
Publicado: (2021)

Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients
por: Zhuo, Zhong-ling, et al.
Publicado: (2018)

Physiologically-Based Pharmacokinetic-Pharmacodynamics Model Characterizing CYP2C19 Polymorphisms to Predict Clopidogrel Pharmacokinetics and Its Anti-Platelet Aggregation Effect Following Oral Administration to Coronary Artery Disease Patients With or Without Diabetes
por: Xu, Ru-jun, et al.
Publicado: (2020)

Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?
por: Bellanti, Francesco, et al.
Publicado: (2011)

Comment on “Association between CYP2C19 and ABCB1 polymorphisms and clopidogrel resistance in clopidogrel-treated Chinese patients”
por: Wang, Bin, et al.
Publicado: (2018)

Pharmacokinetic, pharmacodynamic, and pharmacogenetic assays to monitor clopidogrel therapy
por: Alvitigala, Bhawani Yasassri, et al.
Publicado: (2020)

Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism
por: Afzal, Ashwad, et al.
Publicado: (2016)

Application of Physiologically Based Pharmacokinetic Modeling to Predict Pharmacokinetics in Healthy Japanese Subjects
por: Matsumoto, Yuki, et al.
Publicado: (2018)

Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response
por: Gross, Annette S., et al.
Publicado: (2022)

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant
por: Mehta, Meha P., et al.
Publicado: (2023)

Generalization and fine mapping of European ancestry-based central adiposity variants in African ancestry populations
por: Yoneyama, Sachiko, et al.
Publicado: (2016)

Investigation of CYP3A induction by PF‐05251749 in early clinical development: comparison of linear slope physiologically based pharmacokinetic prediction and biomarker response
por: Lin, Jian, et al.
Publicado: (2022)

Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases
por: Karaźniewicz-Łada, Marta, et al.
Publicado: (2013)

Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry
por: Roelands, Jessica, et al.
Publicado: (2021)

Assessment of the Utility of Physiologically-based Pharmacokinetic Model for prediction of Pharmacokinetics in Chinese and Japanese Populations
por: Yu, Yanke, et al.
Publicado: (2021)

Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
por: Kim, Se-Hyung, et al.
Publicado: (2018)

Association with CYP2C19 polymorphisms and Clopidogrel in treatment of elderly stroke patients
por: Li, Changqing, et al.
Publicado: (2021)

CYP2D6 and CYP2C19 Genes Associated with Tricontinental and Latin American Ancestry of Peruvians
por: Alvarado, Angel T., et al.
Publicado: (2023)

Pharmacokinetics of Tamoxifen and Its Major Metabolites and the Effect of the African Ancestry Specific CYP2D6*17 Variant on the Formation of the Active Metabolite, Endoxifen
por: Kanji, Comfort Ropafadzo, et al.
Publicado: (2023)

Peptide ancestry informative markers in uterine neoplasms from women of European, African, and Asian ancestry
por: Bateman, Nicholas W., et al.
Publicado: (2021)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability
por: Zakaria, Zaril H., et al.
Publicado: (2018)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

The clinical impact of CYP2C19 *2 and *3 polymorphism on Clopidogrel and cost analysis
por: Meman A, Al, et al.
Publicado: (2014)

Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
por: Brown, Sherry-Ann, et al.
Publicado: (2018)

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8‐Mediated Metabolism of Montelukast in Humans
por: Itkonen, Matti K., et al.
Publicado: (2017)

CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic
por: Mirabbasi, Seyed abbas, et al.
Publicado: (2017)

Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke
por: Rath, Charlotte Lützhøft, et al.
Publicado: (2020)

Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
por: Kisor, David F, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7itqdp9ps8mjou6s23piedfbfv